Literature DB >> 32426095

Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases.

Steven D Scoville1, Dimitrios Xourafas1, Aslam M Ejaz1, Allan Tsung1, Timothy Pawlik1, Jordan M Cloyd1.   

Abstract

BACKGROUND: Although surgical resection is associated with the best long-term outcomes for neuroendocrine liver metastases (NELM), the current indications for and outcomes of surgery for NELM from a population perspective are not well understood. AIM: To determine the current indications for and outcomes of liver resection (LR) for NELM using a population-based cohort.
METHODS: A retrospective review of the 2014-2017 American College of Surgeons National Surgical Quality Improvement Program and targeted hepatectomy databases was performed to identify patients who underwent LR for NELM. Perioperative characteristics and 30-d morbidity and mortality were analyzed.
RESULTS: Among 669 patients who underwent LR for NELM, the median age was 60 (interquartile range: 51-67) and 51% were male. While the number of metastases resected ranged from 1 to 9, the most common (45%) number of tumors resected was one. The majority (68%) of patients had a largest tumor size of < 5 cm. Most patients underwent partial hepatectomy (71%) while fewer underwent a right or left hepatectomy or trisectionectomy. The majority of operations were open (82%) versus laparoscopic (17%) or robotic (1%). In addition, 30% of patients underwent intraoperative ablation while 45% had another concomitant operation including cholecystectomy (28.8%), bowel resection (20.2%), or partial pancreatectomy (3.4%). Overall 30-d morbidity and mortality was 29% and 1.3%, respectively. On multivariate analysis, American Society of Anesthesiologists class ≥ 3 [odds ratios (OR), OR = 2.089, 95% confidence intervals (CI): 1.197-3.645], open approach (OR = 1.867, 95%CI: 1.148-3.036), right hepatectomy (OR = 1.618, 95%CI: 1.014-2.582), and prolonged operative time of > 230 min (OR = 1.731, 95%CI: 1.168-2.565) were associated with higher 30-d morbidity while intraoperative ablation and concomitant procedures were not.
CONCLUSION: LR for NELM was performed with relatively low postoperative morbidity and mortality. Concomitant procedures performed at the time of LR did not increase morbidity. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Carcinoid; Cholecystectomy; Intraoperative ablation; Neuroendocrine tumor; Primary tumor resection; Small bowel resection

Year:  2020        PMID: 32426095      PMCID: PMC7215975          DOI: 10.4240/wjgs.v12.i4.159

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  46 in total

1.  Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.

Authors:  M H Chung; J Pisegna; M Spirt; A E Giuliano; W Ye; K P Ramming; A J Bilchik
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

2.  Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.

Authors:  Eugene A Woltering; Brianne A Voros; David T Beyer; Yi-Zarn Wang; Ramcharan Thiagarajan; Pamela Ryan; Anne Wright; Robert A Ramirez; M Jennifer Ricks; J Philip Boudreaux
Journal:  J Am Coll Surg       Date:  2017-01-11       Impact factor: 6.113

3.  Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience.

Authors:  Emin Kose; Bora Kahramangil; Husnu Aydin; Mustafa Donmez; Hideo Takahashi; Federico Aucejo; Allan Siperstein; Eren Berber
Journal:  Surg Endosc       Date:  2019-04-03       Impact factor: 4.584

4.  Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Ioannis D Kostakis; Demetrios Moris; Dimitrios Schizas; Jordan M Cloyd; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

5.  Population level outcomes and costs of single stage colon and liver resection versus conventional two-stage approach for the resection of metastatic colorectal cancer.

Authors:  Jay J Idrees; Fabio Bagante; Faiz Gani; Brad F Rosinski; Qinyu Chen; Katiuscha Merath; Mary Dillhoff; Jordan Cloyd; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2018-09-25       Impact factor: 3.647

6.  Quality of life after treatment of neuroendocrine liver metastasis.

Authors:  Gaya Spolverato; Fabio Bagante; Doris Wagner; Stefan Buettner; Rohan Gupta; Yuhree Kim; Hadia Maqsood; Timothy M Pawlik
Journal:  J Surg Res       Date:  2015-05-29       Impact factor: 2.192

7.  Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database.

Authors:  Mark Fairweather; Richard Swanson; Jiping Wang; Lauren K Brais; Trevor Dutton; Matthew H Kulke; Thomas E Clancy
Journal:  Ann Surg Oncol       Date:  2017-03-16       Impact factor: 5.344

8.  Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.

Authors:  Juan M Sarmiento; Glenroy Heywood; Joseph Rubin; Duane M Ilstrup; David M Nagorney; Florencia G Que
Journal:  J Am Coll Surg       Date:  2003-07       Impact factor: 6.113

9.  Early Morbidity and Mortality after Minimally Invasive Liver Resection for Hepatocellular Carcinoma: a Propensity-Score Matched Comparison with Open Resection.

Authors:  Dimitrios Xourafas; Timothy M Pawlik; Jordan M Cloyd
Journal:  J Gastrointest Surg       Date:  2018-10-30       Impact factor: 3.452

10.  Prolonged survival in a patient with neuroendocrine tumor of the cecum and diffuse peritoneal carcinomatosis.

Authors:  Louis de Mestier; Cindy Neuzillet; Olivia Hentic; Reza Kianmanesh; Pascal Hammel; Philippe Ruszniewski
Journal:  Case Rep Gastroenterol       Date:  2012-04-30
View more
  2 in total

Review 1.  Neuroendocrine liver metastases: a contemporary review of treatment strategies.

Authors:  Jordan M Cloyd; Aslam Ejaz; Bhavana Konda; Mina S Makary; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

Review 2.  [Liver metastases of neuroendocrine tumors].

Authors:  S Nadalin; M Peters; A Königsrainer
Journal:  Chirurgie (Heidelb)       Date:  2022-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.